Cargando…

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia

Detalles Bibliográficos
Autores principales:	Jackson, Nicholas, Khairullah, Shasha, Bee, Ping Chong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175791/ https://www.ncbi.nlm.nih.gov/pubmed/35847726 http://dx.doi.org/10.1002/jha2.54

Ejemplares similares

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
por: Delaporta, P., et al.
Publicado: (2022)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Transfusion Independence Achieved with Combination Fedratinib and Luspatercept in an Elderly Man with Heavily Pretreated Intermediate-2 Risk Primary Myelofibrosis
por: Yun, Nicole K., et al.
Publicado: (2022)

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
por: Delicou, S., et al.
Publicado: (2022)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia
por: Majumder, Anirban, et al.
Publicado: (2020)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

5610224 THE USE OF LUSPATERCEPT IN PATIENTS WITH β -THALASSAEMIA AND MULTIPLE SYSTEMIC COMPLICATIONS INCREASES HEMOGLOBIN LEVEL, DECREASES TRANSFUSION BURDEN, AND IS UNAFFECTED BY COMPLICATIONS. SINGLE THALASSEMIA AND SICKLE CELL DEPARTEMENT’S EXPERIENCE.
por: Manganas, K.M., et al.
Publicado: (2023)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
por: Coates, Thomas D., et al.
Publicado: (2023)

Unexpected Genotype in a Non-Transfusion Dependent Thalassemia Family
por: Curcio, Cristina, et al.
Publicado: (2020)

Post‐transfusion hyperhemolysis syndrome in a patient with beta thalassemia major
por: Kasinathan, Ganesh, et al.
Publicado: (2021)

Molecular Analysis of Non-Transfusion Dependent Thalassemia Associated with Hemoglobin E-β-Thalassemia Disease without α-Thalassemia
por: Phanrahan, Paramee, et al.
Publicado: (2019)

Challenges in transfusion and the role of Thalidomide in E‐β‐Thalassemia—A case report
por: Javed, Rizwan, et al.
Publicado: (2020)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA
por: Guerra, A., et al.
Publicado: (2022)

A Case of Non-Traumatic Avascular Necrosis of Femur in Case of Transfusion-Dependent Thalassemia
por: Mandhani, Geeta, et al.
Publicado: (2017)

Diffuse Hepatic Calcifications in a Transfusion-Dependent Patient with Beta-Thalassemia: A Case Report
por: Saki, Forough, et al.
Publicado: (2013)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Glomerular and Tubular Functions in Children and Adults with Transfusion-Dependent Thalassemia
por: Annayev, Agageldi, et al.
Publicado: (2018)

Pulmonary Functions in Transfusion-Dependent Thalassemia
por: Chandra, Jagdish, et al.
Publicado: (2022)

Resolution of alloimmunization and refractory autoimmune hemolytic anemia in a multi-transfused beta-thalassemia major patient
por: Philip, Joseph, et al.
Publicado: (2014)

Successful Treatment of Acute Chest Syndrome with Manual Exchange Transfusion in a Patient with Sickle Beta(+)-thalassemia
por: Kawahara, Akihiro, et al.
Publicado: (2019)

Kidney transplantation in an adult with transfusion-dependent beta thalassemia: A challenging case report and literature review
por: Kalamara, Tsampika-Vasileia N., et al.
Publicado: (2023)

The need to perform α‐thalassemia genetic testing in Italian patients with β‐thalassemia trait: A case report
por: Santoro, Graziano, et al.
Publicado: (2022)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Alloimmunization among transfusion-dependent thalassemia patients
por: Sadeghian, Mohammad Hadi, et al.
Publicado: (2009)

Glomerular and Tubular Functions in Transfusion-Dependent Thalassemia
por: Sookaromdee, Pathum, et al.
Publicado: (2018)

Quality of life in transfusion-dependent thalassemia patients
por: Alzahrani, Rizqallah A., et al.
Publicado: (2017)

Transfusion Complications in Thalassemia: Patient Knowledge and Perspectives
por: Patterson, Sashoy, et al.
Publicado: (2022)

The transfusion management of beta thalassemia in the United States
por: Lal, Ashutosh, et al.
Publicado: (2021)

Achievement of Pre- and Post-Transfusion Hemoglobin Levels in Adult Transfusion-Dependent Beta Thalassemia: Associated Factors and Relationship to Reduction of Spleen Enlargement
por: Atmakusuma, Tubagus Djumhana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_se3bsci7gfrirok74osllgc70d